다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IBRX

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/29	22:30	Business Wire	ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer	NASDAQ:IBRX	ImmunityBio Inc
2025/01/27	23:00	Business Wire	ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ	NASDAQ:IBRX	ImmunityBio Inc
2025/01/25	10:47	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2025/01/16	07:20	Business Wire	ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency	NASDAQ:IBRX	ImmunityBio Inc
2025/01/16	07:20	Business Wire	ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom	NASDAQ:IBRX	ImmunityBio Inc
2025/01/06	23:00	Business Wire	ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective	NASDAQ:IBRX	ImmunityBio Inc
2025/01/04	06:54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/12/12	22:00	GlobeNewswire Inc.	D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering	NASDAQ:IBRX	ImmunityBio Inc
2024/12/12	20:45	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	21:46	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	21:30	Business Wire	ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	07:28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	07:13	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IBRX	ImmunityBio Inc
2024/12/11	06:24	Business Wire	ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock	NASDAQ:IBRX	ImmunityBio Inc
2024/11/22	00:00	PR Newswire (US)	ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment	NASDAQ:IBRX	ImmunityBio Inc
2024/11/19	23:00	PR Newswire (US)	ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements	NASDAQ:IBRX	ImmunityBio Inc
2024/11/19	22:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/11/19	22:00	Business Wire	ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months	NASDAQ:IBRX	ImmunityBio Inc
2024/11/12	21:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IBRX	ImmunityBio Inc
2024/11/12	21:15	Business Wire	ImmunityBio Reports Third-Quarter 2024 Financial Results	NASDAQ:IBRX	ImmunityBio Inc
2024/10/24	22:00	Business Wire	First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma	NASDAQ:IBRX	ImmunityBio Inc
2024/10/21	22:00	Business Wire	ImmunityBio to Participate in the Jefferies London Healthcare Conference	NASDAQ:IBRX	ImmunityBio Inc
2024/09/09	21:30	Business Wire	ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer	NASDAQ:IBRX	ImmunityBio Inc
2024/08/12	21:46	Business Wire	ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval	NASDAQ:IBRX	ImmunityBio Inc
2024/08/12	21:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IBRX	ImmunityBio Inc
2024/08/06	22:00	Business Wire	ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer	NASDAQ:IBRX	ImmunityBio Inc
2024/07/26	00:02	PR Newswire (US)	Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm	NASDAQ:IBRX	ImmunityBio Inc
2024/07/18	10:48	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/06/20	22:00	Business Wire	ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors	NASDAQ:IBRX	ImmunityBio Inc
2024/06/14	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc

검색 관련기사 보기:NASDAQ:IBRX

1 2 3 4 5 6 7 8 다음 >>

Health Care Select Sector

Invesco QQQ Trust Series 1

American Express

Deutsche Telekom (QX)

JP Morgan Chase

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관